论文部分内容阅读
目的观察重组人干扰素治疗小儿疱疹性咽炎的临床疗效。方法将临床确诊疱疹性咽炎的230例患儿随机分为治疗组和对照组。两组常规预防感染及对症治疗,治疗组123例患儿给予重组人干扰素1μg/(kg.次),1次/d,肌内注射,连续3d;对照组107例患儿给予病毒唑10mg/(kg.d)静脉滴注,1次/d,连续3d。观察治疗前后患儿的临床症状及体征。结果治疗组总有效率(98.38%)、热程(3.74±2.3)d,咽部充血及疱疹平均消退时间(4.64±2.3)d,住院期(6.44±2.1)d;对照组总有效率(80.37%)、热程(4.32±2.6)d,咽部充血及疱疹平均消退时间(6.84±2.3)d,住院期(9.3±1.1)d。治疗组在退热时间、疱疹消退时间及住院期方面明显优于对照组(P<0.05)。结论重组人干扰素治疗小儿疱疹性咽炎可较快改善病情、缩短病程、提高疗效。
Objective To observe the clinical efficacy of recombinant human interferon in the treatment of pediatric herpes pharyngitis. Methods 230 cases of herpes pharyngitis clinically diagnosed were randomly divided into treatment group and control group. Two groups of conventional prevention of infection and symptomatic treatment, the treatment group of 123 children given recombinant human interferon 1μg / (kg. Times), 1 times / d, intramuscular injection, continuous 3d; control group of 107 children given ribavirin 10mg /(kg.d) intravenous infusion, 1 / d, continuous 3d. Observed before and after treatment in children with clinical symptoms and signs. Results The total effective rate (98.38%), heat stroke (3.74 ± 2.3) d, pharyngeal hyperemia and herpes remission (4.64 ± 2.3) d, hospitalization (6.44 ± 2.1) d; 80.37%), duration of fever (4.32 ± 2.6) d, pharyngeal hyperemia and herpes remission (6.84 ± 2.3) d and hospital stay (9.3 ± 1.1) d respectively. The treatment group was significantly better than the control group (P <0.05) in the time of fever relief, herpes regression and hospitalization. Conclusion Recombinant human interferon treatment of children with herpes pharyngitis can quickly improve the condition, shorten the course of disease and improve the curative effect.